Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
BioMarin Pharmaceutical Inc. (BMRN) - free report >>
Geron Corporation (GERN) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioMarin Pharmaceutical Inc. (BMRN) - free report >>
Geron Corporation (GERN) - free report >>
Image: Bigstock
Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3
Sarepta Therapeutics, Inc. (SRPT - Free Report) posted a loss of $1.15 per share in the third quarter of 2016, narrower than the year-ago loss of $1.25. The Zacks Consensus Estimate reported a loss of $1.35 per share.
No revenue was recorded by the company in the reported quarter, as was the case a year ago. The Zacks Consensus Estimate for revenues was $6 million.
Other Details
Research and development expenses registered a decline of 6.5% on a year-over-year basis to $34.3 million, whereas general and administrative expenses surged 47% to $22.2 million.
Sarepta recently gained accelerated approval for Exondys 51 for the treatment of patients suffering from Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
Meanwhile, Sarepta announced that it has dosed the first patient in a phase III study on SRP-4045 and SRP-4053, which is evaluating patients with DMD amenable to exon 45 or 53 skipping.
SAREPTA THERAP Price, Consensus and EPS Surprise
SAREPTA THERAP Price, Consensus and EPS Surprise | SAREPTA THERAP Quote
Zacks Rank & Key Picks
Sarepta currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include BioMarin Pharmaceutical Inc. (BMRN - Free Report) , Geron Corporation (GERN - Free Report) and Exelixis, Inc. (EXEL - Free Report) . While BioMarin and Geron sport a Zacks Rank #1 (Strong Buy), Exelixis carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BioMarin’s loss estimates have narrowed from 28 cents to 25 cents for 2016 and from $1.16 to $1.11 for 2017 over the last 60 days.
Geron has posted a positive earnings surprise in all of the four trailing quarters with an average beat of 20.8%.
Exelixis’ loss estimates have narrowed from 71 cents to 63 cents for 2016 and from 19 cents to a gain of 2 cents for 2017 over the last 60 days. The company has posted a positive earnings surprise twice in the four trailing quarters with an average beat of 9.1%. Its share price has surged 93.6% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>